FR2244493B1 - - Google Patents

Info

Publication number
FR2244493B1
FR2244493B1 FR7329234A FR7329234A FR2244493B1 FR 2244493 B1 FR2244493 B1 FR 2244493B1 FR 7329234 A FR7329234 A FR 7329234A FR 7329234 A FR7329234 A FR 7329234A FR 2244493 B1 FR2244493 B1 FR 2244493B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7329234A
Other languages
French (fr)
Other versions
FR2244493A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLURIPHARM
Original Assignee
PLURIPHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PLURIPHARM filed Critical PLURIPHARM
Priority to FR7329234A priority Critical patent/FR2244493A1/fr
Publication of FR2244493A1 publication Critical patent/FR2244493A1/fr
Application granted granted Critical
Publication of FR2244493B1 publication Critical patent/FR2244493B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/322,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7329234A 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis Granted FR2244493A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7329234A FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7329234A FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Publications (2)

Publication Number Publication Date
FR2244493A1 FR2244493A1 (en) 1975-04-18
FR2244493B1 true FR2244493B1 (enExample) 1977-09-02

Family

ID=9123835

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7329234A Granted FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Country Status (1)

Country Link
FR (1) FR2244493A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
CN100412070C (zh) * 2006-07-07 2008-08-20 山东师范大学 槲皮素衍生物及其制备方法与应用
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242130B2 (en) 2004-10-20 2012-08-14 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8093273B2 (en) 2004-10-20 2012-01-10 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US9199990B2 (en) 2007-02-01 2015-12-01 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8889698B2 (en) 2007-02-01 2014-11-18 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9278940B2 (en) 2012-11-21 2016-03-08 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors

Also Published As

Publication number Publication date
FR2244493A1 (en) 1975-04-18

Similar Documents

Publication Publication Date Title
AU465372B2 (enExample)
AR201235Q (enExample)
AR201231Q (enExample)
AU471343B2 (enExample)
AU465453B2 (enExample)
AU465434B2 (enExample)
AU450229B2 (enExample)
AR201229Q (enExample)
AU472848B2 (enExample)
AU466283B2 (enExample)
AR199451A1 (enExample)
AU477823B2 (enExample)
AR200256A1 (enExample)
AU480004B2 (enExample)
AU471461B2 (enExample)
AR195311A1 (enExample)
AR200885A1 (enExample)
AU447540B2 (enExample)
AR193950A1 (enExample)
AR195948A1 (enExample)
AU477824B2 (enExample)
AU476873B1 (enExample)
AR197627A1 (enExample)
AR196382A1 (enExample)
AR196212Q (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse